SciSparc and Clearmind Innovate with New Patent Application for Binge Behavior Therapy
Overview of the Collaboration
SciSparc Ltd., a company that develops treatments for central nervous system disorders, has teamed up with Clearmind Medicine Inc., a firm focusing on psychedelic therapies for mental health. This collaboration has led to Clearmind filing a European patent application for a unique combination therapy that uses MEAI and N-Acylethanolamines, targeting binge behaviors such as excessive drinking and overeating. To date, the partnership has filed thirteen related patents worldwide. Meanwhile, SciSparc is also advancing cannabinoid-based medications for conditions like Tourette Syndrome and Alzheimer’s disease. Clearmind holds a robust patent portfolio and aims to expand its intellectual property as it explores new therapeutic options.
Positive Outlook
- The European patent application marks an important step in developing innovative treatment options, potentially boosting the companies’ intellectual property.
- This partnership prioritizes research into combination therapies that may effectively tackle significant mental health issues, paving the way for valuable products in the future.
- With thirteen patents filed globally, these efforts showcase active research and innovation which may enhance the companies’ positions in the market.
Challenges Ahead
- The lack of detailed information regarding the progress of the research may raise questions about the transparency and effectiveness of the therapies being developed.
- The focus on Clearmind’s patent filings instead of noteworthy developments from SciSparc may suggest limited advancements within SciSparc itself.
- An emphasis on forward-looking statements introduces uncertainty, which could lead to skepticism among investors about the companies’ future prospects and drug development initiatives.
Frequently Asked Questions
What does the new European patent application cover?
The patent application pertains to a combination therapy using MEAI and N-Acylethanolamines that targets binge behaviors including alcohol consumption and shopping.
Who is SciSparc working with on this research?
SciSparc is collaborating with Clearmind Medicine Inc. to explore innovative combination therapies that include psychedelic molecules and N-acylethanolamines.
How many patents have been filed as part of this collaboration?
Thirteen patents related to this collaboration have been submitted by Clearmind in the United States and in other global regions.
What conditions do SciSparc’s development programs aim to address?
SciSparc is working on treating conditions such as Tourette Syndrome, Alzheimer’s agitation, autism, and status epilepticus.
Where can I learn more about Clearmind Medicine Inc.?
Visit Clearmind Medicine Inc.’s website at https://www.clearmindmedicine.com for more information.
Disclaimer: This summary is generated based on a press release from GlobeNewswire. It may contain inaccuracies. For the complete release, click here.
Stock Activity for $SPRC
Recently, four institutional investors have increased their shares of $SPRC stock, while three have reduced their holdings in the latest quarter.
Details on the largest movements can be found through Quiver Quantitative’s institutional holdings dashboard.
Complete Release
TEL AVIV, Israel, Jan. 06, 2025 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a clinical-stage pharmaceutical company focusing on central nervous system disorder therapies, has announced a partnership with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (FSE: CWY0), a biotechnology firm dedicated to developing psychedelic-derived therapeutics for mental health issues. Clearmind has recently submitted a European patent application for a combination therapy involving MEAI and N-Acylethanolamines, targeting binge behaviors such as alcohol use, overeating, gambling, and compulsive shopping.
Through this collaboration, SciSparc and Clearmind aim to create innovative therapies that combine psychedelic molecules and the N-acylethanolamines group, which includes Palmitoylethanolamide. So far, Clearmind has filed thirteen patents regarding this collaboration in the U.S. and several other international jurisdictions.
About SciSparc:
SciSparc Ltd. (Nasdaq: SPRC) is a pharmaceutical company focused on creating and enhancing cannabinoid-based therapies. The company’s drug development programs include SCI-110 for Tourette Syndrome, treatments for agitation in Alzheimer’s disease, and SCI-210 addressing autism and status epilepticus. Additionally, SciSparc owns a controlling stake in a subsidiary engaged in the sale of hemp oil products on Amazon.com.
About Clearmind Medicine Inc.:
Clearmind is a clinical-stage biotech company focusing on novel psychedelic-derived therapeutics to tackle significant mental health challenges, particularly alcohol use disorders. The company has a strong intellectual property portfolio, currently containing nineteen patent families and 31 granted patents. It plans to pursue further patents as it develops new compounds.
Clearmind shares are traded on Nasdaq under “CMND” and on the Frankfurt Stock Exchange under “CWY0.”
For additional information, please visit:
https://www.clearmindmedicine.com
Forward-Looking Statements:
This press release includes statements categorized as “forward-looking” according to the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that can cause actual outcomes to vary from anticipated results. SciSparc may not update these forward-looking statements unless required by law.
Investor Contact:
IR@scisparc.com
This article was originally published on Quiver News. For the complete story, click here.
The views expressed here are those of the author and do not necessarily represent those of Nasdaq, Inc.
